Kiniksa Pharmaceuticals International (KNSA) Common Equity (2017 - 2026)

Kiniksa Pharmaceuticals International's Common Equity history runs 10 years deep, the most recent figure standing at $605.7 million for Q1 2026.

• Quarterly Common Equity rose 32.39% year-over-year to $605.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $605.7 million (up 32.39% YoY) and the FY2025 annual result came in at $567.6 million, up 29.46% from the prior year.
• Common Equity was $605.7 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $567.6 million in the prior quarter.
• Across five years, Common Equity topped out at $605.7 million in Q1 2026 and bottomed at $153.5 million in Q2 2022.
• A 5-year average of $420.5 million and a median of $435.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity slumped 38.59% — and 2023, when it surged 168.19%.
• Kiniksa Pharmaceuticals International's Common Equity stood at $396.1 million in 2022, then rose by 10.78% to $438.8 million in 2023, then slipped by 0.09% to $438.4 million in 2024, then climbed by 29.46% to $567.6 million in 2025, then grew by 6.71% to $605.7 million in 2026.
• Business Quant data shows KNSA's Common Equity at $605.7 million in Q1 2026, $567.6 million in Q4 2025, and $535.4 million in Q3 2025.